EIF2A and Insulin resistance: These findings are in agreement with our previous reports, where we reported that a neutral CB1R antagonist (AM6545) has the ability to reduce the HFD-induced upregulation in hepatic eIF2α (Tam et al., 2010), and that hepatic activation of CB1R induces ER stress and contributes to insulin resistance (Liu et al., 2012).